SEC Form 4: Prygocki Mark A Sr was granted 3,844 shares

$CRXT
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $CRXT alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
PRYGOCKI MARK A SR

(Last) (First) (Middle)
C/O CLARUS THERAPEUTICS HOLDINGS, INC.
555 SKOKIE BLVD, SUITE 340

(Street)
NORTHBROOK IL 60062

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Clarus Therapeutics Holdings, Inc. [ CRXT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
12/12/2021
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/12/2021 A 3,844(1) A $0.00 3,844 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $4.78 12/12/2021 A 9,610 (2) 12/11/2031 Common Stock 9,610 $0.00 9,610 D
Explanation of Responses:
1. The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 3,844 shares on 12/12/2021, which vests in equal annual installments over three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting date.
2. These options were granted under the 2021 Plan and vest in equal annual installments over a period of three years from the date of grant subject to the Reporting Person having a service relationship as of each such vesting.
Remarks:
/s/ Steven A. Bourne, attorney-in-fact 12/14/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $CRXT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CRXT

DatePrice TargetRatingAnalyst
10/13/2021$10.00Buy
Truist Securities
10/6/2021$12.00Buy
Needham
9/29/2021$13.00Buy
Maxim Group
More analyst ratings

$CRXT
Press Releases

Fastest customizable press release news feed in the world

See more
  • Clarus Therapeutics Holdings, Inc. Announces Completion of Auction for Sale of JATENZO® and Selection of Tolmar, Inc. as Successful Bidder

    Court-supervised auction for JATENZO (testosterone undecanoate capsules; C-III) concluded on October 14, 2022 NORTHBROOK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXTQ), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that, subject to entry into definitive documentation, it and its wholly-owned subsidiary, Clarus Therapeutics, Inc., selected Tolmar, Inc., (Buffalo Grove, IL) as the winning bidder in a competitive bidding and auction proceeding for the sale of JATENZO (and certain related assets). The bidding and auction procedures were approved by the U. S. Ba

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarus Therapeutics Holdings, Inc. Announces Plan for Near-Term Sale of JATENZO® Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

    NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (OTC:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testos

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarus Therapeutics Reports Second Quarter 2022 Financial and Operating Results and Announces Workforce Reduction

    Second quarter 2022 net revenue increased 46% year-over-year to $4.1 million Second quarter 2022 total prescription growth for JATENZO® increased 23% sequentially and increased 72% year-over-year Immediate reduction in workforce by approximately 40% of total headcount; transition of Chief Financial Officer role NORTHBROOK, Ill., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies, today reported financial results for the second quarter of 2022. Clarus also announced that it is pursuing an immediate reduction in staff as i

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRXT
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CRXT
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$CRXT
SEC Filings

See more

$CRXT
Leadership Updates

Live Leadership Updates

See more
  • Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer

    Oragenics, Inc. (NYSE:OGEN) ("Oragenics" or the "Company"), a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck's HPV/Gardasil Franchise. Ms. Murphy joined Oragenics' Board of Directors in 2020. "As a Board Member, Ms. Murphy's extensive experience in the vaccine industry has provided valuable insight for Oragenics' corporat

    $BWV
    $CRXT
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

    Dr. Jumadilova most recently led clinical development programs at Insmed and Pfizer and has nearly 30 years of combined pharmaceutical and biotech experience NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRXT
Financials

Live finance-specific insights

See more
  • Clarus Therapeutics to Report First Quarter 2022 Financial and Operating Results

    NORTHBROOK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its first quarter 2022 financial and operating results on Monday, May 16, 2022, after the market closes. Clarus will host a conference call on Monday, May 16, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 7677008. A live webcast and replay of the conference call will be

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarus Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

    2021 net revenue increased 119% year-over-year to $14.0 million Fourth quarter 2021 net revenue increased 88% year-over-year to $4.6 million Fourth quarter 2021 total prescription growth for JATENZO® increased 11% sequentially and increased 81% year-over-year Conference call and webcast today at 5:15 p.m. ET NORTHBROOK, Ill., March 30, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today reported financial results for the fourth quarter and full year of 2021. "Clarus delivered solid growth in net revenu

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Clarus Therapeutics to Report Fourth Quarter and Full Year 2021 Financial and Operating Results

    NORTHBROOK, Ill., March 29, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. ("Clarus") (NASDAQ:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced it will release its fourth quarter and full year 2021 financial and operating results on Wednesday, March 30, 2022, after the market closes. Clarus will host a conference call on Wednesday, March 30, 2022, at 5:15 p.m. ET to discuss the results. The dial-in numbers are (844) 249-2007 for domestic callers and (224) 619-3902 for international callers. The conference ID number is 5454819. A live webcast and replay of the

    $CRXT
    Biotechnology: Pharmaceutical Preparations
    Health Care

$CRXT
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more